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Introduction
This chapter reviews recent epidemiological data on the
relative contributions of genetic and environmental risk
factors for the development of RA. It considers and pro-
poses the direct and indirect evidence to the contribution
of various risk factors for disease susceptibility. The quality
of the evidence varies and, where appropriate, this is
highlighted.
Genetic factors
Descriptive epidemiology of RA
The descriptive epidemiology of RA is suggestive of a
genetic effect. The occurrence of RA is relatively constant
with a prevalence of between 0.5 and 1.0%, a frequency
that has been reported from several European [1–8] and
North-American populations [9,10]. However, there are
some interesting exceptions (Fig. 1).
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Chapter summary
The prevalence of rheumatoid arthritis (RA) is relatively constant in many populations, at 0.5–1.0%.
However, a high prevalence of RA has been reported in the Pima Indians (5.3%) and in the Chippewa
Indians (6.8%). In contrast, low occurrences have been reported in populations from China and Japan.
These data support a genetic role in disease risk. Studies have so far shown that the familial
recurrence risk in RA is small compared with other autoimmune diseases. The main genetic risk factor
of RA is the HLA DRB1 alleles, and this has consistently been shown in many populations throughout
the world. The strongest susceptibility factor so far has been the HLA DRB1*0404 allele. Tumour
necrosis factor alleles have also been linked with RA. However, it is estimated that these genes can
explain only 50% of the genetic effect. A number of other non-MHC genes have thus been investigated
and linked with RA (e.g. corticotrophin releasing hormone, oestrogen synthase, IFN-γ and other
cytokines). Environmental factors have also been studied in relation to RA. Female sex hormones may
play a protective role in RA; for example, the use of the oral contraceptive pill and pregnancy are both
associated with a decreased risk. However, the postpartum period has been highlighted as a risk
period for the development of RA. Furthermore, breastfeeding after a first pregnancy poses the
greatest risk. Exposure to infection may act as a trigger for RA, and a number of agents have been
implicated (e.g. Epstein–Barr virus, parvovirus and some bacteria such as Proteus and Mycoplasma).
However, the epidemiological data so far are inconclusive. There has recently been renewed interest in
the link between cigarette smoking and RA, and the data presented so far are consistent with and
suggestive of an increased risk.
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Specifically, native American-Indian populations have the
highest recorded occurrence of RA, with a prevalence of
5.3% noted for the Pima Indians [11] and of 6.8% for the
Chippewa Indians [12]. By contrast, there are a number of
groups with a very low occurrence. Studies in rural African
populations, both in South Africa [13] and in Nigeria [14],
failed to find any RA cases in studies of 500 and 2000
adults, respectively. Studies in populations from South-
east Asia [15], including China and Japan [16,17], have
similarly shown very low occurrences (0.2–0.3%).
‘Migrant’ studies
It is clearly difficult from a review of the descriptive epi-
demiological data to know whether environmental or
genetic effects explain the differences between countries.
One handle on this is to consider the occurrence in popu-
lations presumed to be of the same genetic origin but
living in different environments. Such a situation arises by
studying populations that have moved from one environ-
ment to another.
There are a few studies addressing this with respect to
RA. A low occurrence of disease was found in one study
of a Caribbean population of African origin living in Man-
chester, UK, suggesting that the protection to this group
was indeed genetically determined [18]. Similarly, the
investigation of a Chinese population living in an urban
environment in Hong Kong showed the same consistent
low frequency [19]. Recent data have shown, however,
that Pakistanis living in England had a higher prevalence
than those in Pakistan, but it is not as high as the preva-
lence in ethnic English populations [20]. In general, the
data on the geographical occurrence of RA would support
the existence of genetic factors being important and
explaining differences in disease risk.
Familial clustering
The next stage in accruing evidence for genetic risk is to
document an increased occurrence of disease in relatives
of probands compared with the background population
prevalence, so-called familial recurrence risk. Studies of
hospital attendees are subject to bias as there may be a
selection process whereby individuals would more proba-
bly be referred to hospital if they have an affected family
member. Furthermore, several studies rely on family history
as elicited by the proband, which again is subject to bias.
Few studies have been performed comparing familial recur-
rence risk in relatives of cases derived from population
samples with those of controls. Indeed, such studies have
only shown a modest increased risk [21,22]. For example,
a study from the Norfolk Arthritis Register in England
showed only a twofold increased risk [23]. Such an obser-
vation does not negate the role of genetic factors, but
underscores that their contribution to explain disease sus-
ceptibility may be modest. This is important as the familial
recurrence risk is a key factor in determining the power of
genetic linkage studies within affected family pairs. Indeed,
in contrast to other autoimmune diseases such as insulin-
dependent diabetes and multiple sclerosis, the familial
recurrence risk in RA is certainly smaller, thereby making it
harder for studies to identify new genetic factors.
Twin studies
A variant of studies of familial recurrence risk is the com-
parison of disease risk in the initially unaffected co-twin of
monozygotic probands compared with dizygotic
probands. The assumption is that the environmental
sharing between these different twin pair types is the
same and thus any increased disease concordance in the
monozygotic twins confirms the genetic effect. It is impor-
tant in such studies to ensure that it is only like-sexed
dizygotic twin pairs that are compared with the mono-
zygotic twin pairs. However, there may be a greater
environmental concordance in monozygotic twins due, for
example, to psychological and other factors.
Twin studies have consistently showed a fourfold
increased concordance in monozygotic twins compared
with dizygotic twins [24]. This increased risk, however, is
of little value in attempting to quantify the genetic contribu-
tion to disease risk. The concordance between twins is
dependent on the prevalence of disease. As the popula-
tion prevalence approaches 100%, the concordance will
increase accordingly, independent of the true genetic
effect. The appropriate way of quantifying genetic risk is to
assess the heritability based on a series of assumptions of
environmental sharing and genetic sharing between twin
types. Such a study has recently been attempted using
data from both Finnish and English twins [24]. The results
suggest that approximately 50–60% of the occurrence of
disease in the twins is explained by shared genetic effects.
Figure 1
Prevalence of rheumatoid arthritis in various populations. Data from
[1–4,6–9,11,12,16,17].
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Genetic susceptibility factors: human leukocyte antigen
The role of HLA DRB1 alleles as a risk factor of RA has
been known for 25 years. Associations between different
HLA DRB1 alleles have been demonstrated in several
populations across the world [25–31]. Indeed, there have
been few populations where associations have not been
demonstrated.
Interestingly, there do appear to be differences in the
strength of association between different alleles. For
example, HLA DRB1*0404 is a much stronger susceptibil-
ity factor than HLA DRB1*0101 [32] (Table 1). Although it
has been suggested that the susceptibility alleles all share
a single epitope [33], it is difficult to explain the variable
risk under this model. Furthermore, the risk of disease is
related not only to the presence of one single allele, but
also to the full HLA DRB1 genotype [34]. Individuals who
carry the so-called ‘compound heterozygote’ genotype
HLA DRB*0401/*0404 thus have a substantially greater
risk than, for example, individuals who carry single HLA
DRB*0101 alleles.
There is some suggestion that the relationship between
human leukocyte antigen (HLA) and RA may be more
related to the severity of disease, and that the develop-
ment of arthritis per se is only weakly related. Support for
this comes from studies from the Norfolk Arthritis Register
population-based study of inflammatory joint disease in
England [32]. Data from this study show only a weak rela-
tionship between susceptibility to the disease and the
HLA DRB1 genotype (Table 1). The association is fairly
strong in those individuals who satisfy the criteria for RA.
The data show there is an influence of genotype, with
some genotypes having a stronger association as shown.
The HLA region on the short arm of chromosome 6 is a
gene-rich area including several candidate genes that
have an influence on the immune process. One of the
most highly investigated is tumour necrosis factor (TNF).
Studies have shown associations between TNF alleles
and RA [35,36], although one explanation may be linkage
disequilibrium with HLA DRB1. Studies have also sug-
gested, however, that the associations between HLA and
TNF-c1 and TNF-b3 are independent of associations
between HLA and the shared epitope [37]. Other studies
have shown an extended haplotype stretching from HLA
through to TNF that has been implicated in disease [38].
Genetic susceptibility factors: non-MHC genes
Data from twin studies in the HLA association and sharing
studies have been used to estimate that only 50% of the
genetic contribution to RA can be explained by HLA [24].
This has sparked a search for non-MHC genes.
The largest effort has been expanded in some whole
genome screens on affected sibling pair families. Four
such screens have now been undertaken in Europe [39],
the United States [33], Japan [40] and the United
Kingdom [41]. A number of markers emerge from these
studies suggestive of a linkage with RA, although the
linkage with HLA is by far the strongest. One problem is
that such studies often have only a weak power to detect
defects. By contrast, because such studies may be simul-
taneously testing the possibility that any one of 200
regions may be linked with disease, the likelihood of a
false-positive result is also very high. It is for this reason
that it is not surprising studies often fail to replicate results
both between themselves and on further samples within
the population. It is therefore necessary to undertake
further validation studies and more in-depth investigations,
using more closely spaced markers.
An alternative approach is to use a candidate gene
screen where there is no prior reason for looking at a par-
ticular region. Such an approach has been productive,
and evidence has shown that corticotrophin releasing
hormone [42], CYP19 (oestrogen synthase) [43], IFN-γ
[44–46] and other cytokines [47–49] are linked to RA.
Other approaches have addressed the possibility that
genetic regions linked to other autoimmune diseases,
such as insulin-dependent diabetes [50], may also be
linked to RA. Indeed, linkage to a locus on chromosome X
was shown in one study [51]. A further strategy has been
to use results and genome screens on animal models of
arthritis to see whether syntenic regions are also linked to
RA in humans. Such studies have suggested linkage to
17q22 [52].
Whether any of these positive findings discussed will
result in the identification of a true disease susceptibility
mutation remains to be seen. However, one clear problem
is that RA itself is probably heterogeneous and studies
that fail to take notice of this heterogeneity may make it
possible to find a positive result.
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Table 1
Phenotype frequencies of HLA DRB1
Odds ratio 
HLA DRB1 Controls  Cases  (95% confidence 
phenotype (n = 286) (n = 680) interval)
*0101/2 62 155 1.0 (0.8–1.5)
*04 100 306 1.5 (1.1–2.0)
*0401 63 204 1.5 (1.1–2.1)
*0404 10 77 3.5 (1.8–6.8)
*0405/8/9 5 19 1.6 (0.6–4.3)
*1001 3 17 2.4 (0.8–7.8)
SE+ 127 400 1.8 (1.4–2.4)
SE+, shared epitope positive. Data from [32].S268
Environmental factors
The term ‘environment’ is frequently used to describe all
those susceptibility factors leading to disease that are not
explicable on the basis of an identifiable genetic marker. In
a strict sense, however, environment could be taken to
refer to those factors external to the individual; for
example, factors associated with diet, water or air-borne
exposures. It is also important to consider factors impli-
cated with diseases that are internal to the subject without
an obvious genetic basis. An appropriate term for this
group of factors is ‘nongenetic host factors’.
Nongenetic host factors: hormonal and pregnancy
factors
The increased risk of RA in females has lead to consider-
able effort in examining the role of hormonal and preg-
nancy factors in disease occurrence. In general, male sex
hormones, particularly testosterone, are lower in men who
have RA [25]. By contrast, levels of female sex hormones
are not different between RA cases and controls [53].
Interestingly, exogenous hormonal influences are impli-
cated in disease risk. The most widely studied of these is
exposure to the oral contraceptive pill, based on an obser-
vation made over 20 years ago [54] (Fig. 2). There have
been several studies [55] confirming that women who take
the oral contraceptive pill are at reduced risk of developing
RA [25]. There is no clear explanation for this and the
association exists despite the formulation of the oral con-
traceptive pill varying enormously both between popula-
tions and over time. A follow-up of the original study was
undertaken that suggested the oral contraceptive pill was
protective. This showed that the initial protection was lost
on follow-up [56]. One conclusion might therefore be that
oral contraceptive use may postpone, rather than totally
protect against, the development of RA.
Pregnancy itself has been investigated as a risk factor in
RA development. Studies on the influence of pregnancy
on RA have produced conflicting results. A number of
studies [25] have suggested that women who are nulli-
parous are at increased risk of developing the disease,
although there is no increased risk in women who are
single [57]. It would thus appear that subfertility highlights
a group at higher risk.
Recent studies have suggested that pregnancy might also
be important with the interesting observation that the post-
partum period, particularly after the first pregnancy,
represents a strong risk period of disease development
[58,59] (Fig. 3). Subsequent investigations showed that
much of this increased risk could be explained by expo-
sure to breastfeeding and it is women who breastfeed
after their first pregnancy who are at the greatest risk [60].
The suggestion then arose linking breastfeeding with sub-
fertility in so far as RA may be related to either increased
prolactin or abnormal response to prolactin, this latter
hormone being proinflammatory [61].
Nongenetic host factors: other
There have been a number of studies looking at other
comorbidities that have an increased frequency in both
subjects with RA and in their families. The most widely
investigated has been the occurrence of other auto-
immune diseases, particularly type 1 or insulin-dependent
diabetes and autoimmune thyroid disease [62]. Other
diseases, for example schizophrenia, have been shown to
be negatively associated with RA development [63–65].
The significance of these findings is unclear.
Arthritis Research    Vol 4 Suppl 3 Silman and Pearson
Figure 2
The incidence of rheumatoid arthritis in relation to use of the oral
contraceptive pill (OC). Data from the Royal College of General
Practioners’ oral contraception study [54].
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Figure 3
Increased risk of rheumatoid arthritis onset in the postpartum period. *
Relative to nonpregnant periods. Data from [59].
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There have been relatively few studies on anthropometric
factors associated with RA, although one recent
case–control study suggested that people who were
obese were at higher risk [66]. The reason for this is
unclear, and it is not certain whether this may represent a
confounding factor of another exposure or whether people
who are obese have, for example, increased production of
oestrogens, which might pose a risk. A more recent
case–control study found, however, after adjusting for
age, smoking and marital status, that a link with obesity
was nonsignificant [67].
Environmental factors: infection
Indirect evidence
There is much indirect evidence suggesting that exposure
to infectious agents may be the trigger for RA. First, epi-
demiological data come from the observation of a decline
in the incidence of RA in several populations [9,16]. Many
studies have indeed shown a halving in incidence over the
past 30 years [68]. Given the genetically stable popula-
tion, the most probable explanation is that of a decline in
an infectious trigger. This effect of time on occurrence
might also be related to the period of birth as well as to
the current year of observations. The Pima Indians, for
example, showed a decline in occurrence of disease, and
an in-depth study based on analysis of birth cohorts has
shown a decline in the population occurrence of rheuma-
toid factor with increasingly recent birth cohorts [69].
There have been a few studies looking at clustering of RA
in time and space, although there have been reports of
nonrandom clusters occurring within the Norfolk Arthritis
Register population [70]. Other indirect evidence regard-
ing the role of an infectious agent has arisen from
case–control studies suggesting that people who have
had a blood transfusion, even some years prior to disease
onset, may be at an increased risk of disease [66]. Recent
practice has been to screen blood for a number of agents
such as hepatitis, but the increased reporting of blood
transfusion in older cohorts may indeed be explained by
the increased likelihood of infection.
Possible infectious agents
There have been a large number of infectious agents that
have been implicated in RA, including Epstein–Barr virus
and parvovirus, as well as other agents, including bacteria
such as Proteus  and  Mycoplasma. The epidemiological
studies supporting or refuting these possible links are
reviewed elsewhere [25] but, in general, such studies
have been disappointing. One problem for the epidemiolo-
gist is that if RA represents the final common pathway of
exposure to one of several different potential susceptibility
organisms, many of which are also frequently observed in
the general (i.e. nonarthritic population), it makes it more
difficult to confirm a relationship with epidemiological
studies.
Noninfectious environmental factors
There have been remarkably few studies on factors such
as diet, although there is a theoretical basis for investigat-
ing the role of omega-3 fatty acids [71,72]. Randomised
trials suggest that diets high in eicosapentaenoic acid
have a favourable effect on the outcome of RA [73–75].
This might be because such fatty acids compete with
arachidonic acids, the latter of which are involved in
inflammation. Whether such dietary factors have a role in
RA onset is much less clear.
It is perhaps surprising, given how much this exposure has
been investigated in other chronic diseases, that very little
attention has been given to cigarette smoking until
recently. However, findings from a number of recent
studies showed that cigarette smoking is associated with
an increased risk of RA [66,67,76–79] (Table 2). Studies
have also suggested that smoking is related to develop-
ment of rheumatoid factor independent of RA. Indeed, in
many of the epidemiological studies showing a relation-
ship between smoking and RA, the positive findings have
been restricted to those with rheumatoid factor.
Future prospects
There has been considerable recent interest in under-
standing the epidemiology of RA. There have been several
population studies in many different countries around the
world, and observations of differential occurrence (with
time, between populations and between the genders) has
stimulated a number of analytical studies looking for both
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Table 2
Summary of recent epidemiological studies showing the
association between rheumatoid arthritis and cigarette
smoking
Odds ratio 
Cases Controls  Smoking  (95%  confidence 
Study (n)( n) group interval)
[78] 239 239 41–50 pack years 13.5 (2.9–63.4)
Ever 1.8 (1.2–2.2)
Never 1.0
[66] 165 178 Current 0.95 (0.6–1.6)
Ex 1.7 (0.95–3.1)
Never 1.0
[79] 7697 370,000 Current 1.2 (1.1–1.3)
Ex 1.0 (0.95–1.1)
Never 1.0
[67] 361 5851 Current (males) 2.4 (1.5–3.9)
Current (females) 1.1 (0.8–1.6)
Never 1.0S270
genetic and environmental risk factors. Future studies will
benefit from advances in molecular biology techniques to
aid with the identification and characterisation of potential
new genes for RA susceptibility. These studies, as already
described, have revealed some tantalising clues that will
require further follow-up in years to come.
Concluding remarks
RA presents an epidemiological challenge and further elu-
cidation of both genetic and environmental factors,
together with interactions between them, are likely to be
revealed.
Organisations supplying funds for research
Funds can be obtained from the Arthritis Research Cam-
paign [http://www.arc.org.uk] and the Arthritis Foundation
[http://www.arthritis.org].
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